Table 3.
Cells with copy number variations (CNVs) of chromosomes 3, 7, 17 and at 9p21 in urines from 18 cases with bladder cancer
| CNV | 0 | 1 | 2 | 3 | 4 | ≥5 | Total | Loss (CNV <2) | Gain (CNV >2) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| >3 years before diagnosis | CEP 3 | N (%) | 0 (0) | 0 (0) | 350 (100) | 0 (0) | 0 (0) | 0 (0) | 350 (100) | 0 (0) | 0 (0) |
| CEP 7 | N (%) | 0 (0) | 0 (0) | 350 (100) | 0 (0) | 0 (0) | 0 (0) | 350 (100) | 0 (0) | 0 (0) | |
| CEP 17 | N (%) | 0 (0) | 2 (0.6) | 348 (99.4) | 0 (0) | 0 (0) | 0 (0) | 350 (100) | 2 (0.6) | 0 (0) | |
| LSI 9p21 | N (%) | 0 (0) | 0 (0) | 350 (100) | 0 (0) | 0 (0) | 0 (0) | 350 (100) | 0 (0) | 0 (0) | |
| >2 - 3 years before diagnosis | CEP 3 | N (%) | 0 (0) | 0 (0) | 197 (88.3) | 9 (4.0) | 12 (5.4) | 5 (2.2) | 223 (100) | 0 (0) | 26 (11.7) |
| CEP 7 | N (%) | 0 (0) | 1 (0.4) | 198 (88.8) | 10 (4.5) | 9 (4.0) | 5 (2.2) | 223 (100) | 1 (0.4) | 24 (10.8) | |
| CEP 17 | N (%) | 0 (0) | 0 (0) | 198 (88.8) | 8 (3.6) | 10 (4.5) | 7 (3.1) | 223 (100) | 0 (0) | 25 (11.2) | |
| LSI 9p21 | N (%) | 21 (9.4) | 3 (1.3) | 198 (88.8) | 0 (0) | 1 (0.4) | 0 (0) | 223 (100) | 24 (10.8) | 1 (0.4) | |
| >1 - 2 years before diagnosis | CEP 3 | N (%) | 0 (0) | 0 (0) | 256 (92.1) | 7 (2.5) | 14 (5.0) | 1 (0.4) | 278 (100) | 0 (0) | 22 (7.9) |
| CEP 7 | N (%) | 0 (0) | 1 (0.4) | 257 (92.4) | 6 (2.2) | 13 (4.7) | 1 (0.4) | 278 (100) | 1 (0.4) | 20 (7.2) | |
| CEP 17 | N (%) | 0 (0) | 3 (1.1) | 255 (91.7) | 5 (1.8) | 14 (5.0) | 1 (0.4) | 278 (100) | 3 (1.1) | 20 (7.2) | |
| LSI 9p21 | N (%) | 12 (4.3) | 5 (1.8) | 256 (92.1) | 2 (0.7) | 3 (1.1) | 0 (0) | 278 (100) | 17 (6.1) | 5 (1.8) | |
| ≤1 year before diagnosis | CEP 3 | N (%) | 2 (0.4) | 0 (0) | 471 (85.8) | 26 (4.7) | 35 (6.4) | 15 (2.7) | 549 (100) | 2 (0.4) | 76 (13.8) |
| CEP 7 | N (%) | 2 (0.4) | 1 (0.2) | 464 (84.5) | 26 (4.7) | 45 (8.2) | 11 (2.0) | 549 (100) | 3 (0.5) | 82 (14.9) | |
| CEP 17 | N (%) | 2 (0.4) | 3 (0.5) | 469 (85.4) | 24 (4.4) | 33 (6.0) | 18 (3.3) | 549 (100) | 5 (0.9) | 75 (13.7) | |
| LSI 9p21 | N (%) | 22 (4.0) | 8 (1.5) | 484 (88.2) | 14 (2.6) | 20 (3.6) | 1 (0.2) | 549 (100) | 30 (5.5) | 35 (6.4) | |
| After diagnosis | CEP 3 | N (%) | 0 (0) | 0 (0) | 695 (97.7) | 3 (0.4) | 7 (1.0) | 6 (0.8) | 711 (100) | 0 (0) | 16 (2.3) |
| CEP 7 | N (%) | 0 (0) | 1 (0.1) | 694 (97.6) | 3 (0.4) | 7 (1.0) | 6 (0.8) | 711 (100) | 1 (0.1) | 16 (2.3) | |
| CEP 17 | N (%) | 0 (0) | 1 (0.1) | 694 (97.6) | 2 (0.3) | 5 (0.7) | 9 (1.3) | 711 (100) | 1 (0.1) | 16 (2.3) | |
| LSI 9p21 | N (%) | 10 (1.4) | 2 (0.3) | 695 (97.7) | 1 (0.1) | 3 (0.4) | 0 (0) | 711 (100) | 12 (1.7) | 4 (0.6) |